Background: Human papillomavirus (HPV) vaccination coverage is characterized by geographic disparities in the United States, with national studies finding lower coverage in rural versus nonrural areas. To direct quality improvement efforts in North Carolina, we sought to understand how different rurality measures characterize these disparities.
Methods: We used separate negative binomial regression models to test associations between five dichotomized county-level rurality measures and HPV vaccination coverage (≥1 dose) among North Carolina adolescents, aged 11 to 12 years (n = 326,345). Rurality measures were derived from: Office of Management and Budget's Metropolitan Statistical Areas, Rural-Urban Continuum Codes, Index of Relative Rurality, US Census Bureau classifications, and North Carolina Rural Center classifications. Models controlled for Social Vulnerability Index (SVI) percentile and rate of pediatricians per county. Vaccination data came from the North Carolina Immunization Registry.
Results: HPV vaccination coverage was 29% across North Carolina's 100 counties (range: 13%, 46%). Agreement between rurality measures ranged from 54% to 93% of counties. In adjusted analyses, none of the five rurality measures were correlated with HPV vaccination coverage, but higher SVI and higher rate of pediatricians were positively associated with coverage (P < 0.01). Exploratory moderation analyses suggested regional variation in the relationship between rurality and coverage, with a positive association in one region, a negative association in one region, and no association in four regions.
Conclusions: County-level rurality measures did not identify disparities in HPV vaccination coverage in North Carolina.
Impact: Measures related to social vulnerability and access to pediatricians may be better suited for understanding and addressing the state's substantial county-level vaccination disparities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717598 | PMC |
http://dx.doi.org/10.1158/1055-9965.EPI-24-1186 | DOI Listing |
J Cancer Educ
January 2025
School of Nursing, Fudan University, 305 Fenglin Road, Shanghai, 200032, China.
This qualitative study explores the decision experiences of adult women regarding HPV vaccination, highlighting their decision needs, outcomes, and expected support. A qualitative descriptive study design was used. A semi-structured interview guide based on the Ottawa Decision Support Framework (ODSF) was used to interview Chinese women (aged 18 to 45).
View Article and Find Full Text PDFInt Med Case Rep J
January 2025
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin Hospital, Bandung, Indonesia.
Anogenital warts (AGW) including multiple types of human papillomavirus (HPV) are prevalent. In this context, oncogenic HPV infection leads to anogenital cancers and the lesion is more persistent. Several research on AGW therapy with measles, mumps, and rubella (MMR) vaccine injections have been successful without adverse effects.
View Article and Find Full Text PDFACG Case Rep J
January 2025
Gastroenterology and Hepatology, University of Arizona College of Medicine - Tucson, Tucson, AZ.
Rectal squamous metaplasia in inflammatory bowel disease is rare. We present 2 cases of rectal squamous metaplasia, one in a patient with Crohn's disease and another with ulcerative colitis. Given the risk of malignant transformation, dysplasia surveillance is important particularly in areas of chronic inflammation.
View Article and Find Full Text PDFJ Nanobiotechnology
January 2025
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Discipline of Intelligent Instrument and Equipment, Department of Experimental Medicine, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, China.
The numerous high-risk carcinogenic types of human papillomavirus (HR-HPV) that lack vaccine protection underscore the urgent need to develop broader-spectrum HPV vaccines. This study addresses this need by focusing on HR-HPV types 53, 56, and 66, which are not currently targeted by existing vaccines. It introduces an effective method for their soluble expression, as well as that of their mutants, within an Escherichia coli expression system.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!